可溶性Fms样酪氨酸激酶-1与脓毒症急性呼吸窘迫综合征风险及死亡率相关
这项前瞻性队列研究纳入198例符合Sepsis-2标准的危重症脓毒症患者,在急诊入院时采集血浆用电化学发光法测定sFlt-1,按柏林标准定义ARDS。结果显示29%的患者6天内发生ARDS;sFlt-1每升高1个对数单位,ARDS风险OR 1.91(95%CI 1.31-2.76,p<0.01),死亡风险OR 2.19(95%CI 1.57-3.08,p<0.01)。因果中介分析显示ARDS介导了sFlt-1对死亡总效应的20.3%(95%CI 6.9-98.1%,p<0.01)。作者认为血浆sFlt-1作为脓毒症相关ARDS和死亡的早期内皮治疗靶点值得进一步研究。
要点
- 脓毒症患者急诊入院时血浆sFlt-1每升高1个对数单位,ARDS风险OR 1.91(95%CI 1.31-2.76,p<0.01)。
- 同一人群中sFlt-1每升高1个对数单位,死亡风险OR 2.19(95%CI 1.57-3.08,p<0.01)。
- ARDS介导了sFlt-1对死亡总效应的20.3%(95%CI 6.9-98.1%,p<0.01)。
- 198例脓毒症患者中29%在6天内发生ARDS(柏林标准)。
- 作者认为血浆sFlt-1作为脓毒症相关ARDS和死亡的早期内皮治疗靶点值得进一步研究。
适用人群与场景
- 符合Sepsis-2标准的危重症脓毒症患者,共198例,急诊入院时纳入。
- ARDS按柏林标准定义,发生于入院后6天内。
诊断标准与关键阈值
- 脓毒症诊断采用Sepsis-2标准。
- ARDS诊断采用柏林标准。
研究设计与关键结果
- 研究类型为前瞻性队列研究,纳入198例符合Sepsis-2标准的危重症脓毒症患者,急诊入院时采集血浆,用电化学发光法测定sFlt-1。
- 29%的患者在6天内发生ARDS(柏林标准)。
- sFlt-1与ARDS风险的关联:校正年龄、性别及脓毒症肺源性与非肺源性来源后,OR 1.91(每log升高;95%CI 1.31-2.76;p<0.01)。
- sFlt-1与死亡风险的关联:校正年龄、性别及脓毒症肺源性与非肺源性来源后,OR 2.19(每log升高;95%CI 1.57-3.08;p<0.01)。
- 因果中介分析:ARDS介导sFlt-1对死亡总效应的20.3%(95%CI 6.9-98.1%;p<0.01)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 作者结论:血浆sFlt-1水平较高与ARDS风险增加相关,ARDS介导了脓毒症期间sFlt-1相关死亡的显著比例;研究结果进一步提示VEGF信号失调参与ARDS,并认为血浆sFlt-1作为脓毒症相关ARDS和死亡的早期内皮治疗靶点值得进一步研究。
对床旁实践的改变
- 作者认为血浆sFlt-1作为脓毒症相关ARDS和死亡的早期内皮治疗靶点值得进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The vascular endothelial growth factor (VEGF) signaling pathway is important in the pathogenesis of acute respiratory distress syndrome (ARDS) with supportive genetic and proteomic evidence. Genetic polymorphisms within FLT1, which encodes VEGF receptor 1, associate with risk of ARDS in sepsis. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is a secreted splice variant of FLT1 that acts as a potent antagonist to circulating VEGF.
OBJECTIVES: To assess the association between early plasma concentrations of sFlt-1 and risk of ARDS and to determine if ARDS mediates the relationship between sFlt-1 and mortality during sepsis.
DESIGN, SETTING, AND PARTICIPANTS: In a prospective cohort study, we enrolled 198 critically ill patients with sepsis per Sepsis-2 criteria. ARDS was defined per Berlin criteria.
MAIN OUTCOMES AND MEASURES: Levels of sFlt-1 were quantified using electrochemiluminescence on plasma collected in the emergency department upon admission. We tested the association between plasma levels of sFlt-1 with ARDS and mortality using logistic regression adjusting for age, sex, and pulmonary versus nonpulmonary source of sepsis. We applied causal mediation analysis to determine the percentage of the total effect of sFlt-1 on mortality that was mediated by ARDS.
RESULTS: We enrolled 198 patients; ARDS developed within 6 days in 29%. Plasma levels of sFlt-1 were significantly associated with risk of ARDS in sepsis (odds ratio [OR], 1.91 per log increase; 95% CI, 1.31-2.76 per log increase; p < 0.01). Plasma sFlt-1 levels were also associated with mortality (OR, 2.19 per log increase; 95% CI, 1.57-3.08 per log increase; p < 0.01). ARDS mediated 20.3% (95% CI, 6.9-98.1%) of the total effect of sFlt-1 on mortality (p < 0.01).
CONCLUSIONS AND RELEVANCE: Higher plasma levels of sFlt-1 were associated with an increased risk of ARDS and ARDS mediated a significant proportion of the sFlt-1-associated mortality observed during sepsis. Our findings further implicate dysregulated VEGF signaling in ARDS and suggest that plasma sFlt-1 merits further investigation as an early endothelial therapeutic target for sepsis-associated ARDS and mortality.
参考来源
- Jones TK, Reilly JP, Anderson BJ, et al. Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis. Crit Care Explor. 2025. PMID: 40794402. doi:10.1097/CCE.0000000000001294
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。